A new personalised vaccine could halve the risk of skin cancer returning in high-risk patients, a large trial has found.

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna…

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted…

Merck and Moderna’s personalized mRNA cancer vaccine helps prevent melanoma recurrence and spread, raising hopes for use against other cancers.